🏢 官网IRKVUEDoubao · 实盘不做把握 9/10不做原因:无增量信息
北京时间·🕒 发布 05:00:00(美东 10-21 17:00)·⟳ 抓取 05:05:09回填·⚡ 决策 10-22 05:21:00·5.8 天前
Kenvue宣布将于2026年10月30日盘前公布三季报，因金佰利收购 pending 而取消业绩电话会
这是一份纯程序性IR通知：只告知Q3财报将于10月30日盘前发布及取消电话会，没有任何收入、利润、指引、并购条款或审批的新增事实；取消电话会是pending并购的自然安排，不改变交易完成概率或对价，股票层面无预期差、无可交易edge。
📄 原文KVUE↗ 原文
Kenvue to Announce Third Quarter 2026 Results on October 30, 2026
SUMMIT, N.J.--(BUSINESS WIRE)-- Kenvue Inc. (NYSE: KVUE) will announce its third quarter 2026 financial results before…
不做 Kenvue Inc.（KVUE.US）
纯程序性财报日期公告（10/30盘前发财报、因并购在途取消电话会），无业绩、指引、交易条款或审批的新增事实，不构成可交易催化；实际业绩待10月30日另行研判
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Kenvue仅公告三季报发布时间（10月30日盘前）并因金佰利收购在途而取消电话会，无任何财务或交易增量信息，属程序性日期通知，不构成事件驱动交易机会。
🔎 新鲜度:最早出现 2026-10-21 · 扩散 low · price-in 风险 low ↗
主要风险
- 10月30日实际财报可能带来波动，但那是下一独立事件，不能用本次日期公告提前下注
- 并购若在财报前意外宣布交割或破裂将改变标的属性，当前公告无此信号
反向证据
- 做多前查反向 · 来源 kb_search · 日期 2026-10-20 · 影响 none
近72小时已处理记录显示交易已获中国SAMR（10/10）、巴西、欧盟、澳洲放行，KMB已完成49亿美元收购融资票据定价；本公告未在此之外新增任何利好，且此前判断KVUE股价已贴近收购隐含对价
检索:Kenvue Kimberly-Clark 交易最新进展 审批 交割
先例如何影响了这次决策
对本次决策的影响:确认无可交易催化，直接AVOID；实际业绩反应留待10月30日财报事件单独研判
方向:无先例支持方向性交易：财报日期公告本身不含基本面信息
涨幅量级:未做事件研究——纯排期通知无可校准的涨跌幅量级
形态:不适用
工具执行结果 · 成功 1 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 1,801 ms
{"result": "search_processed_events:agent query=`kenvue kimberly-clark pending transaction no conference call | kenvue third quarter 2026 results date october 30 | kvue q3 2026 earnings announcement`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 72.0/72 小时、27233 条本臂决策(完整)，返回 6 条候选。\n• 10-20 14:10 UTC(北京 22:10) [ticker]
原文全文
展开原文 · 1,007 字
SUMMIT, N.J.--(BUSINESS WIRE)--
Kenvue Inc. (NYSE: KVUE) will announce its third quarter 2026 financial results before the market opens on October 30, 2026. Due to the pending transaction with Kimberly-Clark, Kenvue will not be hosting a quarterly conference call to review its financial results.
The press release will be available on the company’s website at
investors.kenvue.com
.
About Kenvue
Kenvue Inc. is the world’s largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno
®
, BAND-AID
®
Brand, Johnson’s
®
, Listerine
®
, Neutrogena
®
and Tylenol
®
, are science-backed and recommended by healthcare professionals around the world. At Kenvue, we realize the extraordinary power of everyday care. Our teams work every day to put that power in consumers’ hands and earn a place in their hearts and homes. Learn more at
www.kenvue.com
.
Investor Relations:
Kenvue_IR@Kenvue.com
Media Relations:
Media@Kenvue.com
Source: Kenvue
Kenvue Inc. (NYSE: KVUE) will announce its third quarter 2026 financial results before the market opens on October 30, 2026. Due to the pending transaction with Kimberly-Clark, Kenvue will not be hosting a quarterly conference call to review its financial results.
The press release will be available on the company’s website at
investors.kenvue.com
.
About Kenvue
Kenvue Inc. is the world’s largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno
®
, BAND-AID
®
Brand, Johnson’s
®
, Listerine
®
, Neutrogena
®
and Tylenol
®
, are science-backed and recommended by healthcare professionals around the world. At Kenvue, we realize the extraordinary power of everyday care. Our teams work every day to put that power in consumers’ hands and earn a place in their hearts and homes. Learn more at
www.kenvue.com
.
Investor Relations:
Kenvue_IR@Kenvue.com
Media Relations:
Media@Kenvue.com
Source: Kenvue
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
4f4fe58511· 2026-10-22 05:21 · doubao / doubao-seed-evolving-latest-version · 策略包658c0c1e2ba5当前